AUTHORS
Jonathon Le, MD, Seoyon Lee, MD2, Ionela Iacobas Jr, MD3, Senthil Sukumar, MD,MSc4
AFFILIATIONS
1 Baylor College of Medicine, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 Baylor College of Medicine, Houston, Texas, United States
ABSTRACT
Background: Hereditary hemorrhagic telangiectasia (HHT) causes chronic mucosal bleeding and visceral arteriovenous malformations, both of which may affect iron balance. In patients with pulmonary arteriovenous malformations (PAVMs), right-to-left shunting may produce chronic hypoxemia and increase erythropoietic iron requirements. The Epistaxis Severity Score (ESS) quantifies nasal bleeding but may not reflect other blood loss or physiologic iron demand. We examined whether PAVM status and HHT genotype were associated with iron stores.
Methods: We performed a retrospective cross-sectional study of 25 adults in a single-center HHT registry. The primary outcome was baseline ferritin according to documented PAVM status. ESS and hemoglobin were examined as clinical measures of epistaxis and anemia. All baseline values were collected at time of first hematology clinic visit within our center of excellence. Among patients with ENG or ACVRL1 variants, we compared ferritin and PAVM prevalence by genotype. Because of the small cohort, comparisons used exact Wilcoxon rank-sum or Fisher exact tests. Sensitivity analyses repeated the ferritin comparisons among women and evaluated the PAVM–ferritin relationship using an exact genotype-stratified rank test. Analyses used available cases without imputation or multivariable modeling.
Results: In our cohort, median age was 42 years (IQR, 34–60), 18 patients (72%) were women, and 10 (40%) were PAVM-positive. Genetic testing identified ACVRL1 variants in 11 patients (44%), ENG in 7 (28%), and SMAD4 in 3 (12%); 4 patients (16%) met clinical Curaçao criteria without a reported molecular diagnosis. Ferritin was available for 23 patients.
Ferritin, ESS, and hemoglobin did not differ significantly by PAVM status. Median ferritin was 13 ng/mL (IQR, 9.3–23) in PAVM-positive patients and 38 ng/mL (IQR, 27–56) in PAVM-negative patients (P=.086). Corresponding median ESS values were 4.71 (IQR, 1.92–7.28) and 4.17 (IQR, 2.43–6.59; P=.795), and median hemoglobin values were 11.0 g/dL (IQR, 9.9–12.2) and 12.8 g/dL (IQR, 11.1–14.2; P=.169).
PAVMs occurred in 5/7 patients with ENG variants (71%) and 2/11 with ACVRL1 variants (18%; P=.049). Median ferritin was 13 ng/mL with ENG and 37 ng/mL with ACVRL1 (P=.033). Because all ENG patients were women, comparisons were repeated among women only: median ferritin was 11.5 vs 33.5 ng/mL by PAVM status (positive vs negative; P=.111) and 13 vs 36 ng/mL by genotype (ENG vs ACVRL1; P=.097). Within the ENG subgroup, median ferritin was 13 ng/mL in PAVM-positive patients (n=5) and 16.5 ng/mL in PAVM-negative patients (n=2); within the ACVRL1 subgroup, the corresponding medians were 9.15 ng/mL (n=2) and 41 ng/mL (n=8), respectively (exact genotype-stratified P=.133).
Conclusions: In this small, single-center HHT cohort, PAVM status was not significantly associated with ferritin, hemoglobin, or ESS at the first hematology visit. Nevertheless, the observed trend toward decreased ferritin pattern among PAVM-positive patients despite comparable ESS raises the possibility that epistaxis severity alone may not fully reflect iron balance in patients with pulmonary vascular involvement. PAVMs were more common among ENG patients, who also had lower median ferritin than ACVRL1 patients; however, clustering of PAVMs within ENG and the exclusively female ENG subgroup prevented the contributions of PAVM status, genotype, and sex from being distinguished.
Clinically, these findings reinforce direct assessment of ferritin and other iron indices rather than inferring iron stores from ESS or hemoglobin alone. The data do not establish PAVM status or ENG genotype as independent risk factors for iron depletion but identify a potential pulmonary vascular–iron phenotype for further study. Investigation in a larger longitudinal, multicenter registry such as CHORUS is needed to determine whether PAVM-associated shunt physiology and molecular subtype are associated with iron stores beyond what is reflected by ESS, while accounting for PAVM burden and treatment, oxygen saturation, gastrointestinal and menstrual bleeding, iron-replacement therapy, and longitudinal ferritin measurements.
DISCLOSURES
Jonathon Le, MD: No relevant conflicts of interest to declare.